119 related articles for article (PubMed ID: 38423245)
1. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.
Miele E; Anghileri E; Calatozzolo C; Lazzarini E; Patrizi S; Ciolfi A; Pedace L; Patanè M; Abballe L; Paterra R; Maddaloni L; Barresi S; Mastronuzzi A; Petruzzi A; Tramacere I; Farinotti M; Gurrieri L; Pirola E; Scarpelli M; Lombardi G; Villani V; Simonelli M; Merli R; Salmaggi A; Tartaglia M; Silvani A; DiMeco F; Calistri D; Lamperti E; Locatelli F; Indraccolo S; Pollo B
Cancer Lett; 2024 Apr; 588():216711. PubMed ID: 38423245
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
4. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiles of long- and short-term glioblastoma survivors.
Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional diversity of long-term glioblastoma survivors.
Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
[TBL] [Abstract][Full Text] [Related]
8. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
9. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
11. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
13. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
14. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
[TBL] [Abstract][Full Text] [Related]
15. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW
Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334
[TBL] [Abstract][Full Text] [Related]
16. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
17. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
18. Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping.
Lyon JF; Vasudevaraja V; Mirchia K; Walker JM; Corona RJ; Chin LS; Tran I; Snuderl M; Richardson TE; Viapiano MS
Acta Neuropathol Commun; 2021 Jun; 9(1):120. PubMed ID: 34193272
[TBL] [Abstract][Full Text] [Related]
19. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.
Lu J; Cowperthwaite MC; Burnett MG; Shpak M
PLoS One; 2016; 11(4):e0154313. PubMed ID: 27124395
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
